Latest Advances in Tumor-Agnostic Strategies for NTRK Fusion-Positive Cancer

Welcome to the Oncology Brothers podcast! In this episode, hosts Drs. Rahul and Rohit Gosain, practicing community oncologists, share their key takeaways from a session on NTRK Fusion Positive Solid Malignancies, they moderated during a satellite event at ASCO 2025 in partnership with Medscape Global Oncology.Join us as we discuss:•⁠ ⁠The prevalence of NTRK fusions in various cancers and why community oncologists should be aware of them.•⁠ ⁠The importance of comprehensive next-generation sequencing (NGS) for detecting these fusions across diverse histologies.•⁠ ⁠Available treatment options, including first-generation NTRK inhibitors like larotrectinib and entrectinib, and their efficacy in improving overall and progression-free survival.•⁠ ⁠Insights into the CNS activity of these treatments and the common side effects patients may experience.•⁠ ⁠Special considerations for pediatric patients, including formulation challenges and the potential for re-challenging with NTRK inhibitors.Don't forget to check out the full accredited enduring program by Medscape Global Oncology linked below, and earn your CME credit. https://www.medscape.org/viewarticle/1002679?src=acdmpart_onc-brothers_1002679 Follow us on social media:•⁠ ⁠X/Twitter: https://twitter.com/oncbrothers•⁠ ⁠Instagram: https://www.instagram.com/oncbrothers•⁠ Website: https://oncbrothers.com/#entrectinib #larotrectinib #repotrectinib